Frazier Life Sciences Management’s Enliven Therapeutics ELVN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,050,483	Closed	-$14.3M	–	51
2023 Q3	$14.3M	Buy	1,050,483 +219,500	+26%	+$3M	0.95%	26
2023 Q2	$17M	Hold	830,983	–	–	1.01%	26
2023 Q1	$18.2M	Buy	+830,983	New	+$18.2M	1.32%	22